Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 1 Interventional

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

NCT00496665
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Vandetanib, Cyclophosphamide, Methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound

NCT02078011
View directory record Official record
Conditions
Breast Fibroadenoma
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
David R. Brenin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated Not applicable Interventional

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

NCT01351844
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Education and exercise intervention, Education and General Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated Phase 1Phase 2 Interventional

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

NCT04278144
View directory record Official record
Conditions
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
Interventions
BDC-1001, Nivolumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344
View directory record Official record
Conditions
Solid Tumors, Breast Cancer
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Sorafenib in Treating Patients With Metastatic Breast Cancer

NCT00096434
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 29, 2026, 5:12 AM EDT
Not listed No phase listed Observational

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

NCT01273909
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Acquired Lymphedema, Congenital Lymphedema
Interventions
Perforator Flap Breast Reconstruction, Vascularized Lymph Node Transfer
Procedure
Lead sponsor
The National Institute of Lymphology
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)

NCT03365895
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer, Neuropathy;Peripheral, Neuropathy
Interventions
Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 29, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Weight Management Among Breast Cancer Survivors

NCT02387671
View directory record Official record
Conditions
Body Weight
Interventions
Device: FitBit Flex wrist band, Device: FitBit Aria weight scale, Diet Intake Messages, Behavioral Counseling
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT01105312
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
172
States / cities
Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 29, 2026, 5:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

NCT02287675
View directory record Official record
Conditions
Breast Cancer
Interventions
Lymphoseek, Sulfur Colloid
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 29, 2026, 5:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer

NCT00960401
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 29, 2026, 5:12 AM EDT
Completed No phase listed Observational

Outcomes of a Deep Inferior Epigastric Perforator Flap Program

NCT00543907
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Percutaneous Removal and Margin Ablation for Breast Cancer

NCT00574301
View directory record Official record
Conditions
Breast Cancer
Interventions
Percutaneous Removal and Margin Ablation
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts

NCT03288792
View directory record Official record
Conditions
Breast Cancer
Interventions
RI8 device imaging
Device
Lead sponsor
Real Imaging Ltd.
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Laguna Hills, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Mindfulness for Breast Cancer

NCT02647216
View directory record Official record
Conditions
Anxiety, Depression, Breast Cancer
Interventions
Mindfulness Based Cognitive Therapy, Treatment as Usual
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 29, 2026, 5:12 AM EDT
Recruiting Phase 2 Interventional

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
6
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

NCT05064085
View directory record Official record
Conditions
Hormone Receptor-positive Breast Cancer
Interventions
Cemiplimab, Capecitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
LEE011, Buparlisib, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

NCT02796755
View directory record Official record
Conditions
Inflammation, Fatigue
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Results available

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
Interventions
Fruquintinib (HMPL-013)
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 29, 2026, 5:12 AM EDT